Press Release vs Conference Abstract vs Peer-Reviewed Paper vs Regulatory Decision
A plain guide to the kinds of sources behind health headlines, from press releases and conference abstracts to preprints, journal papers and regulatory decisions, and what each can and cannot show.
Content last updated . This page has not been medically reviewed.
Same study, very different sources
A health claim can reach you through a press release, a conference poster, an early online draft, a journal paper or a regulator's decision. These are not interchangeable. Each one has a different job, a different level of checking, and different ways of being wrong. Knowing which one you are looking at is often the fastest way to judge how much weight a claim deserves.Source types at a glance
| Source | What it is | What it can tell you | What it cannot tell you |
|---|---|---|---|
| Press release | A summary written to attract attention, often by a university or company | That a study exists and who ran it | Whether the summary matches the paper |
| Conference abstract | A short description of work presented at a meeting | Early, preliminary results | Final results, full methods or harms |
| Preprint | A full draft posted before journal review | Complete methods and data as the authors saw them | That the results have been independently checked |
| Peer-reviewed paper | A journal article reviewed by outside experts | Full methods, results and limits | That the finding is correct or will hold up |
| Trial registry record | A public description of a planned or running trial | What was planned and its status | Whether the treatment works |
| Regulatory decision | A regulator's decision about one product and use | That a product met that regulator's standard for a stated use | That every similar product or use is supported |
Press releases
Press releases are written to be read, not to be audited. A study of 462 press releases from 20 UK universities, compared with the papers behind them, found exaggerated advice in 40% (95% confidence interval 33% to 46%), exaggerated causal claims in 33% (26% to 40%), and exaggerated inference to humans from animal research in 36% (28% to 46%). [1] The same study found that news stories were much more likely to exaggerate when the press release did. [1] That is one set of releases from one country and year, so it shows a pattern to watch for, not a rate for every release.Conference abstracts
An abstract is a brief report, often given before the work is finished. In one analysis of abstracts from a single European endocrinology congress, 1,205 abstracts were featured and 341 (28.3%) were later published as full papers. [2] That is one meeting in one field, so do not treat the figure as typical. The practical point is that many abstracts never become papers you can read, and when they do, the details may differ. Treat an abstract as a pointer, not a finding.Preprints
A preprint is a complete and public draft not yet certified by peer review, and any part of it, including results and conclusions, may change after review. [3] bioRxiv states that its articles are not peer-reviewed, edited or typeset before posting. [4] In one comparison, peer-reviewed articles had somewhat better reporting quality than the preprints they came from, but the difference was small. [5] Peer review improved reporting. It did not make the result certain. More on this in Preprints vs Peer-Reviewed Papers.Peer-reviewed papers
Journal review is a useful filter, not a guarantee. Among highly cited clinical studies, 16% were later contradicted and another 16% had found effects stronger than later work. [6] Papers can also be corrected or retracted. See Corrections and Retractions in Health Research.Regulatory decisions
A regulatory decision is the most specific source type, and the easiest to over-read.- United States, drugs and biologics. To be approved, a company must demonstrate that the product is safe and effective for its intended use. [7] The FDA review team examines the submitted data and decides whether to approve. [8]
- Devices. A 510(k) clearance rests on showing the device is substantially equivalent to a device already legally marketed in the United States. [9] Read the product's own record for what was tested in people.
- "Registered" is not "approved." FDA says registration of an establishment or listing of a drug or device does not denote approval. [7]
- European Union. EMA's committee gives a recommendation on whether a medicine should be marketed, and the European Commission grants the authorization. EMA itself has no authority to permit marketing in the member countries. [10]
- Off-label. A drug approved for one use may still be prescribed for another, but FDA has not determined that it is safe and effective for that unapproved use. [11]
Always name the regulator, the exact product and the exact use. An approval for one product or indication does not carry over to a look-alike product.
Where trials sit
Trial phases are steps, not verdicts. Phase 2 studies typically involve a few hundred patients and are not large enough to show whether a drug will be beneficial, while Phase 3 studies are designed to test benefit in a specific population. [12] See Clinical-Trial Phases Explained.A safety note
No source type here is advice for you personally. Do not start, stop or change a medicine because of a headline, abstract or preprint. Talk with the prescriber.Frequently asked questions
Is a conference abstract the same as a published study?
No. An abstract is a short early report and many never become full papers. In one analysis of a single congress, 28.3% were later published in full. [2]
If a study is peer reviewed, can I trust it?
Peer review is a check, not proof. Some well-cited clinical findings were later contradicted or turned out weaker. [6]
Why do news stories and press releases sound more certain than the paper?
Releases are written to attract attention, and exaggeration in them is linked with exaggeration in the news. [1]
Does "FDA registered" mean "FDA approved"?
No. Registering an establishment or listing a drug or device does not mean approval. [7]
Are preprints unreliable?
They are unreviewed drafts, so results can change. [3] In one comparison, preprints were only slightly less complete in reporting than the journal versions. [5]
References
- Sumner P and colleagues, The association between exaggeration in health related science news and academic press releases (BMJ 2014). Read 2026-10-22.
- Endocrine 2021, Publication outcome of research presented at the European Congress of Endocrinology. Read 2026-10-22.
- NLM, NIH Preprint Pilot. Read 2026-10-22.
- bioRxiv, About bioRxiv. Read 2026-10-22.
- Carneiro CFD and colleagues, Comparing quality of reporting between preprints and peer-reviewed articles in the biomedical literature (Research Integrity and Peer Review 2020). Read 2026-10-22.
- Ioannidis JPA, Contradicted and initially stronger effects in highly cited clinical research (JAMA 2005). Read 2026-10-22.
- FDA, Is It Really "FDA Approved"?. Read 2026-10-22.
- FDA, Step 4: FDA Drug Review. Read 2026-10-22.
- FDA, Overview of Device Regulation. Read 2026-10-22.
- EMA, Authorisation of medicines. Read 2026-10-22.
- FDA, Understanding Unapproved Use of Approved Drugs "Off Label". Read 2026-10-22.
- FDA, Step 3: Clinical Research. Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.